Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Pasireotide for postoperative pancreatic fistula.

Allen PJ, Gönen M, Brennan MF, Bucknor AA, Robinson LM, Pappas MM, Carlucci KE, D'Angelica MI, DeMatteo RP, Kingham TP, Fong Y, Jarnagin WR.

N Engl J Med. 2014 May 22;370(21):2014-22. doi: 10.1056/NEJMoa1313688. Erratum in: N Engl J Med. 2014 Jul 3; 371(1):94.

2.

The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial.

Ma LW, Dominguez-Rosado I, Gennarelli RL, Bach PB, Gonen M, D'Angelica MI, DeMatteo RP, Kingham TP, Brennan MF, Jarnagin WR, Allen PJ.

Ann Surg. 2017 Jan;265(1):11-16. doi: 10.1097/SLA.0000000000001892.

PMID:
27429029
3.

Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis.

Denbo JW, Slack RS, Bruno M, Cloyd JM, Prakash L, Fleming JB, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MH.

J Gastrointest Surg. 2017 Apr;21(4):636-646. doi: 10.1007/s11605-016-3340-7. Epub 2017 Jan 3.

PMID:
28050766
4.

Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes.

Abbott DE, Sutton JM, Jernigan PL, Chang A, Frye P, Shah SA, Schauer DP, Eckman MH, Ahmad SA, Sussman JJ.

J Surg Oncol. 2016 Jun;113(7):784-8. doi: 10.1002/jso.24239. Epub 2016 Apr 4.

PMID:
27041733
5.
6.

Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis.

Goyert N, Eeson G, Kagedan DJ, Behman R, Lemke M, Hallet J, Mittmann N, Law C, Karanicolas PJ, Coburn NG.

Ann Surg. 2017 Jan;265(1):2-10. doi: 10.1097/SLA.0000000000001889.

PMID:
27537539
7.

[Perioperative treatment with pasireotide reduces the rate of postoperative pancreatic fistula].

Strobel O, Büchler MW.

Chirurg. 2014 Sep;85(9):823. doi: 10.1007/s00104-014-2858-z. German. No abstract available.

PMID:
25113091
8.

Role of octreotide in the prevention of postoperative complications following pancreatic resection.

Büchler M, Friess H, Klempa I, Hermanek P, Sulkowski U, Becker H, Schafmayer A, Baca I, Lorenz D, Meister R, et al.

Am J Surg. 1992 Jan;163(1):125-30; discussion 130-1.

PMID:
1733360
9.

Duct-to-Mucosa vs Invagination for Pancreaticojejunostomy after Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial from a Single Surgeon.

Bai X, Zhang Q, Gao S, Lou J, Li G, Zhang Y, Ma T, Zhang Y, Xu Y, Liang T.

J Am Coll Surg. 2016 Jan;222(1):10-8. doi: 10.1016/j.jamcollsurg.2015.10.003. Epub 2015 Oct 21.

PMID:
26577499
10.

Pasireotide for prevention of pancreatic leak: Is there light at the end of the tunnel?

Ramesh H.

Natl Med J India. 2014 Sep-Oct;27(5):268-9. No abstract available.

PMID:
26037428
11.

Temporary fibrin glue occlusion of the main pancreatic duct in the prevention of intra-abdominal complications after pancreatic resection: prospective randomized trial.

Suc B, Msika S, Fingerhut A, Fourtanier G, Hay JM, Holmières F, Sastre B, Fagniez PL; French Associations for Surgical Research.

Ann Surg. 2003 Jan;237(1):57-65.

12.

Pasireotide for postoperative pancreatic fistula.

Yang F, Jin C, Fu D.

N Engl J Med. 2014 Aug 28;371(9):875. doi: 10.1056/NEJMc1407470#SA1. No abstract available.

PMID:
25162895
13.

Pasireotide for postoperative pancreatic fistula.

Allen PJ.

N Engl J Med. 2014 Aug 28;371(9):875-6. doi: 10.1056/NEJMc1407470. No abstract available.

14.

Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery.

Welsch T, Müssle B, Distler M, Knoth H, Weitz J, Häckl D.

Langenbecks Arch Surg. 2016 Nov;401(7):1027-1035. Epub 2016 May 28. Review.

PMID:
27233242
15.

Prospective Evaluation of Pasireotide in Patients Undergoing Pancreaticoduodenectomy: The Washington University Experience.

Dominguez-Rosado I, Fields RC, Woolsey CA, Williams G, Horwedel TA, Rose JB, Hammill CW, Doyle MB, Chapman WC, Strasberg SM, Hawkins WG, Sanford DE.

J Am Coll Surg. 2017 Nov 11. pii: S1072-7515(17)32066-5. doi: 10.1016/j.jamcollsurg.2017.10.021. [Epub ahead of print]

PMID:
29133263
16.

Systematic review and meta-analysis of somatostatin analogues in the prevention of postoperative complication after pancreaticoduodenectomy.

Jin K, Zhou H, Zhang J, Wang W, Sun Y, Ruan C, Hu Z, Wang Y.

Dig Surg. 2015;32(3):196-207. Review.

17.

Somatostatin analogues for pancreatic surgery.

Gurusamy KS, Koti R, Fusai G, Davidson BR.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008370. doi: 10.1002/14651858.CD008370.pub3. Review.

PMID:
23633353
18.

Clinical evaluation of somatostatin use in pancreatic resections: Clinical efficacy or limited benefit?

Anderson RJ, Dunki-Jacobs E, Callender GG, Burnett N, Scoggins CR, McMasters KM, Martin RC 2nd.

Surgery. 2013 Oct;154(4):755-60; discussion 760. doi: 10.1016/j.surg.2013.07.001.

PMID:
24074412
19.

External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy: prospective multicenter randomized trial.

Pessaux P, Sauvanet A, Mariette C, Paye F, Muscari F, Cunha AS, Sastre B, Arnaud JP; Fédération de Recherche en Chirurgie (French).

Ann Surg. 2011 May;253(5):879-85. doi: 10.1097/SLA.0b013e31821219af.

PMID:
21368658
20.

Transampullary pancreatic duct stenting decreases pancreatic fistula rate following left pancreatectomy.

Fischer CP, Bass B, Fahy B, Aloia T.

Hepatogastroenterology. 2008 Jan-Feb;55(81):244-8.

PMID:
18507117

Supplemental Content

Support Center